Pharmacokinetics/Pharmacodynamics of TP-271 in the MRSA Pneumonia Model (RA-13-6071)

StatusFinished
Effective start/end date10/06/13 → 9/06/14

Funding

  • Tetraphase Pharmaceuticals Inc.: $76,484.50
View all
View less

Keywords

  • Biotechnology & Drug Development, Infectious Diseases